Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC22688 AZD 3676 A novel potent, combined serotonin 5-HT1A and 5-HT1B receptor antagonist with Ki of 0.13 and 2.4 nM in brain homogenates, respectively.
DC11986 OX03050 A novel potent, competitive squalene synthase inhibitor that upregulate the LDLR in mouse and human liver cell lines with EC50 of 26 nM.
DC20692 ASP 8477 A novel potent, highly selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 of 0.99, 1.65 and 57.3 nM for human FAAH-1, FAAH-1 (P129T) and FAAH-2, respectively.
DC21507 PHA-408 A novel potent, highly selective, ATP-competitive IKK-2 inhibitor with IC50 of 40 nM, 350-fold selectivity over IKK-1.
DC23309 BCL6 inhibitor 8c A novel potent, in vivo-active BCL6 inhibitor with IC50 of 0.1 uM in ELISA assays.
DC21209 KW-2581 A novel potent, irreversible and orally active inhibitor of steroid sulfatase (STS) with IC50 of 13 nM in ZR-75-1 cells.
DC11769 MPO-IN-28 Featured A novel potent, irreversible Myeloperoxidase (MPO) inhibitor with IC50 of 44 nM.
DC21058 GNS-1481 A novel potent, irreversible, T790M mutant-selective inhibitor of mutant EGFR with IC50 of 6.2, 3.4 and 4.2 nM for L858R-T790M, T790M and Del19-T790M, respectively.
DC21059 GNS-1486 A novel potent, irreversible, T790M mutant-selective inhibitor of mutant EGFR with IC50 of 8.3, 4.2 and 4.3 nM for L858R-T790M, T790M and Del19-T790M, respectively.
DC11612 KBP-7018 hydrochloride A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively.
DC11611 KBP-7018 A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively.
DC11751 UHC1 A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism.
DC11750 SR-1664 Featured SR-1664 is a novel potent, non-agonist PPARγ ligand that blocks the Cdk5-mediated phosphorylation in vitro (IC50=80 nM) and in vivo, without the classical agonism.
DC11968 OSU-03013 A novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 2 uM.
DC24024 Z-360 A novel potent, orally active CCK-2/gastrin receptor antagonist with Ki of 0.47 nM.
DC11607 JTZ-951(Enarodustat) Featured A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2.
DC11608 JTZ-951 hydrochloride A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2.
DC11546 Azeloprazole sodium A novel potent, orally active proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM.
DC21707 STX-681 A novel potent, orally active, dual-acting aromatase and steroid sulfatase (STS) inhibitor with ICI0 of 0.82 nM and 39 nM, respectively.
DC11599 PF-739 A novel potent, pan-AMPK activator with similar potency for all AMPK heterotrimers.
DC20806 BMS-852927 A novel potent, partial LXRβ-selective agonist (EC50=9 nM) with 20% LXRα and 88% LXRβ activity compared to a full pan agonist in transactivation assays.
DC11610 AKS1-IN-19 A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3.
DC22745 SLx-4090 Featured A novel potent, selective and orally active enterocytic microsomal triglyceride transfer protein (MTP) inhibitor that inhibits only MTP localized to enterocytes with IC50 of 6 nM.
DC11696 CM-579 A novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 16 nM and 32 nM for G9a and DNMT1, respectively.
DC21667 SMM-295 A novel potent, selective cannabinoid receptor 2 (CB2) agonist with Ki of 12 nM, >30-fold selectivity over CB1.
DC20841 BRD6989 Featured A novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex.
DC11953 MU 380 A novel potent, selective CHK1 inhibitor 2 nM, >80-fold selectivity over CHK2.
DC11982 CX815 A novel potent, selective CXCR2 inhibitor with IC50 of 0.4 nM.
DC11981 CX4152 A novel potent, selective CXCR2 inhibitor with IC50 of 7.6 nM.
DC11827 9-ING-41 Featured 9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia